Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Transcranial red/near-infrared light therapy for lingering sleepiness in obstructive sleep apnea

Official title: Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness (STILL TIRED)

Run by NYU Langone Health · NCT06698809 · Data updated 2026-11-12

This trial will test whether gentle red/near-infrared light to the head (tPBM) can reduce ongoing daytime sleepiness in people with moderate-to-severe obstructive sleep apnea who use CPAP.

More Obstructive Sleep Apnea trials

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment22 (estimated)
SponsorNYU Langone Health
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedJanuary 12, 2026
Main results expectedSeptember 1, 2026
Study endsOctober 3, 2026
Registry record updatedJanuary 14, 2026
Trial IDNCT06698809 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with moderate-to-severe OSA who have used CPAP regularly for at least three months, remain sleepy (ESS ≥8), and are cognitively normal are the ideal candidates.

Probably not a fit

People with chronic insomnia, circadian rhythm disorders, central sleep apnea, current supplemental oxygen use, recent night-shift work, or who are not compliant with CPAP are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a pilot interventional study testing transcranial photobiomodulation (tPBM), which uses red and near-infrared light applied to the scalp, as a potential way to reduce residual sleepiness in treated OSA patients. Participants will be adults with moderate-to-severe OSA who have been using CPAP regularly and continue to report daytime sleepiness. The study will collect short-term clinical outcome measures of sleepiness using standard questionnaires and will gather preliminary neural data to explore potential mechanisms. The primary aim is to generate first-of-its-kind pilot data to inform larger trials.

Why it matters

Potential benefit: If successful, tPBM could provide a noninvasive option to reduce residual daytime sleepiness in OSA patients who remain sleepy despite effective CPAP therapy.

How similar studies have gone: tPBM has shown effects on cerebral blood flow and metabolism in other populations, but applying tPBM to reduce sleepiness in OSA is novel and has not been previously tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Cognitively normal (Telephone Interview for Cognitive Status (TiCS) ≥29))
* Moderate - severe OSA
* Currently on therapy for OSA and has received treatment for OSA for at least 3 months.
* Sustained compliance with continuous positive airway pressure (CPAP), which means using the machine at least 4 hours per night for five nights a week.
* Epworth Sleepiness Score (ESS) greater than or equal to 8 or excess daytime sleepiness as defined by the Functional Outcome Sleep Questionnaire or clinical complaint.

Exclusion Criteria:

* Documented diagnosis of chronic insomnia, or sleep onset insomnia based on Insomnia Severity Index (ISI)
* Documented diagnosis of circadian rhythm disorder
* Any current use of supplemental oxygen
* Other sleep-related breathing disorders (central sleep apnea, etc.) based on American Academy of Sleep Medicine (AASM) criteria
* Current shift work involving night shift (regular work between 12am and 6am or night shift) within the past 6 months
* Anticipated scheduled bariatric surgery within the next 3 months
* Chronic regular (\> 2 nights per week) use of any sedative, stimulant, neuroleptic drugs, or other medications limiting validity of cognitive tests. This includes regular use of alcohol or marijuana for sleep. Melatonin is ok.
* Diagnosis of uncontrolled psychiatric disease in the last six months, and/or history of schizophrenia or bipolar disorder. Controlled conditions will include major depressive disorder, panic disorder, schizoaffective disorder, generalized anxiety disorder, Obsessive-compulsive disorder (OCD), substance use disorders, and alcohol abuse/dependence. Personality disorders and neurodevelopmental disorders (e.g. autism, ADHD) are allowed if cognition is within normal limits.
* Taking methylphenidate for ADHD.
* Presence of other critical comorbid conditions that would lead to inability to complete the study protocol (including follow-up for 2 years), or that would affect cognition (e.g. clinically relevant endocrine or hematological conditions).
* Chronic regular (\> 2 nights per week) use of stimulant if unable to complete a washout prior to MRI.
* Does not have a regular sleeping environment (i.e., sleeps in a different setting \> 2 nights per week).
* Currently pregnant or planning to become pregnant.
* Prior diagnosis of a Central nervous system (CNS) disease, such as multiple sclerosis, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, a loss of consciousness \> 24 hours, or traumatic brain injury as identified by the Cumulative Illness Rating Scale for Geriatrics (CIRS). Participants who are diagnosed with Mild cognitive impairment (MCI) or Alzheimer's disease based on neuropsychological testing will be excluded. Delirium in the last 12 months.
* Near-miss or prior automobile accident "due to sleepiness" within the past 12 months.
* Employed as a commercial driver during the study (for example, bus drivers, train engineers, airplane pilots) or construction worker.
* Past intolerance or hypersensitivity to tPBM.
* Significant skin conditions (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that are found in the area of the procedure sites.
* Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment.
* Any type of implants in the head, whose functioning might be affected by tPBM (e.g., stent, clipped aneurysm, embolized arteriovenous malformation (AVM), implantable shunt - Hakim valve).
* Failure to meet standard MRI safety requirements (e.g., claustrophobia, non-removable piercings, implanted medical devices, other non-removable metals) as determined by the MRI Safety Checklist.

Where it's running

  • NYU Langone Health
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.